Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Inst ...

Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, ...

Designing a Phase 2 trial of CTX-009 in combination with chemotherapy in patients with DLL4-positive colorectal cancer (CRC) treated in the second ... targets PD-1 and PD-L1 and exhibits a unique ...

According to the researchers, this new discovery could help scientists understand how to tackle colon cancer more effectively ...

For more specifics regarding certepetide's mechanism of action ... you can see that we're working -- we have ongoing trials in pancreatic cancer and appendiceal cancer, colon cancer, glioblastoma, ...

Development Portfolio Highlights Certepetide as a treatment for solid tumors in combination with other anti-cancer agents Certepetide is an investigational drug designed to selectively activate the ...

Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, ...

Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...

NCI via biorender.com RAS genes are the second most frequently mutated genes in cancer, and mutant RAS proteins are key ...

However, disruptions to this balance, such as from infections or dietary changes, can impair goblet cell function, ...

A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, will be holding a webinar to run through new clinical data from the ...